Since December 2019 the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.